In conclusion, ARID1A may regulate the cell cycle state and apoptosis of GBM cells, and ARID1A KD may enhance the therapeutic resistance response of GBM to TMZ, thereby promoting the ability of glioma cells to resist TMZ in vitro. The gene discussed is ARID1A; the disease is central nervous system cancer.